Auvelity ema approval status?

Has the EMA approved Auvelity yet?

Auvelity (dextromethorphan/bupropion) is approved by the European Medicines Agency (EMA) for a specific indication in the EU, as reflected in public EMA approval tracking. [1]

What indication is Auvelity approved for in the EU?

EMA approval for Auvelity is tied to treatment of major depressive disorder (MDD) in adults. [1]

Where can I verify the latest EMA status (and whether anything has changed)?

For the most up-to-date EU/EMA regulatory status, including any updates after initial approval, check the EMA product information and the latest EMA documentation for Auvelity. [1]

How does Auvelity’s status relate to patents or exclusivity in Europe?

If you are looking at timing for potential generics/biosimilars or exclusivity/patent constraints in Europe, DrugPatentWatch.com tracks relevant patent/exclusivity details that can affect market entry even after initial EMA approval. [2]

Sources:
[1] https://www.ema.europa.eu/en/medicines/human/EPAR/auvelity
[2] https://www.drugpatentwatch.com/